Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2079

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 2079
---
 to other filings.

    Exhibit No.
     
    Description

    2.1
     
    Business Combination Agreement, dated as of June 4, 2023, by and among
    Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc., as amended (incorporated by reference to Exhibit
    2.1 to the Current Report on Form 8-K filed by Phoenix Biotech Acquisition Corp. with the Securities and Exchange Commission on June
    5, 2023).

    2.2
     
    Amendment No. 1 to the Business Combination Agreement, dated as of
    February 5, 2024, by and among Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc. (incorporated
    by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Phoenix Biotech Acquisition Corp. with the Securities and
    Exchange Commission on February 6, 2024).

    2.3
     
    Amendment No. 2 to the Business Combination Agreement, dated as of
    February 13, 2024, by and among Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc. (incorporated
    by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Phoenix Biotech Acquisition Corp. with the Securities and
    Exchange Commission on February 13, 2024).

    3.1
     
    Second Amended and Restated Certificate of Incorporation of CERo Therapeutics
    Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K/A filed by CERo Therapeutics Holdings,
    Inc. with the Securities and Exchange Commission on February 27, 2024).

    3.2
     
    Second Amended and Restated Bylaws of CERo Therapeutics Holdings, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K/A filed by CERo Therapeutics Holdings, Inc. with the Securities and Exchange Commission on February 27, 2024).

    3.3
     
    Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock